Research Aims Sample Clauses

Research Aims. “Research Aims” shall have the meaning ascribed to such term in the CRADA, as summarized in Exhibit B of this Agreement.
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
Research Aims. In order to gain a full appreciation of next generation institutional transnationalism, the study explores the following. First it describes and analyses the patterns of next generation inclusion across a range of philanthropic and political transnational organizations. Second, it investigates the form, frequency and impact of next generation institutionalized activities. Third, the study examines the factors that contribute to the emergence of next generation institutionalized activities. Amongst these factors, particular attention is paid to human variables, opportunity structures, processes of socialization, and individual volition, and how next generation institutionalized transnationalism affects assimilation and incorporation within the United States. The research on these aspects of next generation transnationalism has been organized around five key aims. These are outlined below, and briefly positioned in relation to related works. Furthermore, some brief details are provided on how these aims are addressed. This chapter then outlines the structure of the thesis, before concluding with a brief section on important aspects of the terminology used in the study. Aim 1: Determine the patterns of next generation inclusion within transnational organizations Previous studies that have explored institutional (Xxxxx-Xxxxxx, 2005; Xxxxx and Xxxxxx, 2008) and non- institutional (Xxxxxx and Xxxxxx, 2002; Xxxxxxx, 2002; Xxxxxxxx et al., 2002) transnational activities among individuals born and/or raised in the United States predict mostly limited involvement - at rates that are significantly lower than the parental generation. This study therefore examines to what extent this also applies to their involvement in transnational organizations, paying particular attention to variations in an attempt to isolate factors and organizational characteristics that could explain next generation inclusion or exclusion. Aim 2: Examine the form and frequency of next generation institutional transnationalism Itzigsohn and Xxxxxxx (2002) distinguished between ‘broad’ and ‘narrow’ forms of transnational activities: the former designated occasional practices and the latter more regular commitments. This study investigates the positions and responsibilities that next generation individuals have assumed within their respective organizations, and the impact their contributions have generated in order to consider to what extent their contributions conform to ‘broad’ or ‘narrow’ defin...
Sample 1Sample 2
Research Aims. To fill these research gaps, the present research uses secondary data analysis of two national datasets related to drug and MAT use: the National Surveys on Drug Use and Health and the Treatment Episodes Datasets. Use of nationally-representative data among adults and a specific focus on differences by opioid use type enable generalizable findings that forecast needs in order to strategically plan targeted prevention and treatment interventions. This dissertation research aims to:
Sample 1
Research Aims. The IOM revised guidelines include a call for increased research surrounding GWG. AI/AN women are a unique population to the United States with high rates of maternal obesity and diabetes. There needs to be more research surrounding the effects of prepregnancy BMI and GWG during pregnancy and subsequent pregnancy outcomes to help guide clinical management of high-risk pregnancies among AI/AN women. The primary objective of this study is to investigate the individual and joint effects of high prepregnancy BMI and excess GWG on fetal macrosomia using a retrospective cohort study of AI/AN women. A sub-analysis of only non-diabetic women will be conducted to account for the possible confounding of diabetes. The secondary aim of this analysis is to display the associations of macrosomia with these two main exposures for each individual state to look at possible geographic differences.
Sample 1
Research Aims. In summary, the literature regarding the “gateway” phenomenon in the context of the current tobacco and marijuana market and social norms landscape is limited, with additional research needed to more fully characterize who is most likely to initiate use overall using distinct products and the subsequent use patterns that evolve based on which product was first used. This paper aims to contribute to the literature by examining tobacco and marijuana use outcomes (i.e., number of products ever used or currently used) in relation to first product used among ever users of tobacco or marijuana, as well as characterizing those who initially use the distinct tobacco products or marijuana. METHODS
Sample 1
Research Aims. ‌ The primary research questions that this paper will address are concurrent with those that shaped the research design for the Latrine Training Mat study (referred to in this paper as the WASH-LTM study). In order to ascertain whether the latrine training mat could be considered a feasible tool, it was necessary to first understand the context of rural Western Kenya and how it influences children’s defecation practices – particularly those that take place between the ages of two and five years old. It was hypothesized that, during this age range, children were developmentally capable of learning to use the latrine, but this learning process was often delayed due to specific contextual barriers. Consequently, this study aimed to first identify the local perceptions and practices that related to this issue, and then to evaluate how the latrine training mat could be used and would be perceived within the local context. The following are the three questions that shaped the LTM research design, and which will direct the discussion put forth in this paper. Research Question 1: What are the current practices surrounding child defecation, feces disposal, and toilet training in rural Western Kenya? Research Question 2: What are the perceived benefits and limitations of the latrine training mat for households in rural Western Kenya? Research Question 3: Is the latrine training mat a feasible tool for effectively facilitating latrine use and behavior change among young children and their mothers? Chapter 2: Literature Review‌
Sample 1
Research Aims. The aim of this study was to identify the genetic cause of NSC. Initially we planned to map areas of homozygosity within the genome of NSC patients by utilising SNP linkage analysis and homozygosity mapping with platforms such as HomozygosityMapper and BeadStudio. This was followed by WES analysis. Through the data generated, potential strong candidate genes were identified and prioritised based on their encoded proteins function and tissue distribution of expression, primarily in the liver and biliary tract. Subsequently, by direct sequencing of the genes, we aimed to confirm the disease causing mutations and the potential effect of the gene product in the manifestation of NSC.
Sample 1
AutoNDA by SimpleDocs
Research Aims. All the work you do is headed towards publications in peer-reviewed journals and conferences. The number of publications expected depends on your situation. For example, if you are enrolled in a master’s thesis program, you can expect to publish 1 journal and 2 conference papers. If you are enrolled in a doctoral program, expect to have 3 journal papers and 6 conferences publications. Conferences could include SPIE Medical Imaging, ISBI, IPCAI & CARS, MICCAI, ICCR, MR in RT Symposium. Attitude for successful research: If you are new to research, you need to realize that it is fundamentally different than academic assignments. Research involves developing novel knowledge. This means that it has never been done before and there is a risk of not meeting the objectives. Because this lab is concerned with ‘applying’ existing knowledge in Computer Science, that risk is reduced. Once meeting a “roadblock”, successful researchers will investigate the reasons behind it. You will need to be diligent, detail-oriented but also committed and perseverant. Once the cause(s) of the ‘roadblock’ is identified, you will be best placed to propose solutions and alternatives. Another key is communication. Communicating what you worked on, what you are working on, and any impediment is paramount. Dr. Xxxxx has an open-door policy, schedules frequent 1-on-1 meetings and we hold lab meetings to facilitate communication. Training goals: As a member of the research team, you can expect to gain translational skills within several areas of Computer Science; you will be trained in image processing, best development practices and you will be provided with a unique opportunity to learn and revisit concepts learned in the classrooms. We work together to create a personalized and focused training plan for your professional insertion.
Sample 1

Related to Research Aims

  • Research Support opioid abatement research that may include, but is not limited to, the following:

  • Research Program 2.1 University will use reasonable efforts to conduct the Research Program described in Attachment A which is hereby incorporated in full by reference (“Research Program”), and will furnish the facilities necessary to carry out said Research Program. The Research Program will be under the direction of _____________________ (“Principal Investigator”), or his or her successor as mutually agreed to by the Parties and will be con­ducted by the Principal Investigator at the University.

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.

  • Research Funding Genocea shall pay to Isconova in total [* * *] payable as follows: (i) $[* * *] in equal monthly installments for each remaining month in 2009 following the Effective Date and (ii) $[* * *] in equal monthly installments during the period from January 1, 2010 until March 31, 2012. The Research Funding shall be used solely for the performance of activities under the Research and Phase 1 Supply Plan and the Development and Scale-Up Plan and, for the avoidance of doubt, solely to fund Development and research activities for human (and not veterinary) applications in accordance with such Research and Phase 1 Supply Plan and Development and Scale-Up Plan. Notwithstanding anything to the contrary above, the Parties agree that this restriction shall only apply to the allocation and use of the Research Funding as such, and shall not be construed as limiting or affecting the ownership of any Isconova Technology and Joint Technology created, conceived, reduced to practice or Invented hereunder. Isconova’s ownership and/or rights to the Isconova Technology and Joint Technology shall exclusively be governed by the provisions in Section 3.3. and Isconova’s use of the Isconova Technology and Joint Technology shall be subject only to the licenses granted to Genocea in Sections 3.1.1 through 3.1.3. Isconova shall during the Research Term allocate not less than two (2) dedicated FTEs for Isconova’s research work for Genocea hereunder and each such dedicated FTE shall be paid through Research Funding. During the Research Term, Isconova shall, within fifteen (15) days after the end of each month, deliver to Genocea a report setting forth the number of Isconova FTEs that worked on activities under the Development and Scale-Up Plan and the Research and Phase 1 Supply Plan, as well as other costs and expenses of Isconova evidencing recourses spent on Isconova’s research work hereunder. Researching Funding THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. payments shall be made within fifteen (15) days after the end of each calendar month.

  • Research Program Funding 3.1.1 Pfizer will fund the research to be performed by Rigel, pursuant to the Agreement, according to the following schedule: COMMITMENT YEAR ANNUAL COMMITMENT 1 $2,350,000.00 2 $2,350,000.00 The funding payments of two million three hundred and fifty thousand dollars ($2,350,000.00) shall support the work of the equivalent of ten (10) full time employees ("FTEs") of Rigel.

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Research Program Term The Research Program shall be conducted during the period of five years commencing as of the Agreement Date ("Research Program Term"). Upon not later than seventy-five (75) days' prior written notice JT may, in its sole judgment, terminate the Research Program at the end of the third (3/rd/) year and fourth (4/th/) year of the Research Program. The RMC may terminate the Research Program any time during the Research Program Term if it unanimously determines the Research Program is no longer scientifically useful or that all potential Products would not be commercially viable. In case of such an early termination by JT or the RMC, JT shall be exempt from any payment(s) under Section 10(a) that would have become due and payable after the effective date of such early termination. Following any termination of the Research Program (i) that occurs simultaneously with the termination of this Agreement in accordance with Section 13 (i.e., no compound or Lead Compound has been designated previously a Collaboration Lead Compound in accordance with Section 3(b) and no Independent Lead Compound is being developed in accordance with Section 3(m)) or (ii) that is followed at some future date by the termination by JT of Development or co-promotion of any Collaboration Lead Compound and/or Product pursuant to Sections 3(l) or 5(c), respectively, or development of an Independent Lead Compound in accordance with Section 3(m) (A) any licenses granted by Tularik to JT will terminate, (B) JT will grant to Tularik an exclusive, sublicensable, worldwide license, to make, use and sell compounds, Collaboration Lead Compounds or Products under JT's interest in Program Patents and Program Know-How and (C) under the terms and conditions to be separately agreed, JT will also grant to Tularik a nonexclusive, sublicensable, worldwide license under any JT Patent Rights and Know-How to the extent necessary to practice the license granted under the Program Patents and Program Know-How in (B) (including, with respect to compounds, a limited number of JT's library compounds approved by JT); provided, however, that in the event the Research Program terminates but the Agreement has not terminated with respect to designated Collaboration Lead Compounds, Independent Lead Compounds and/or Products as provided in Section 2(g)(ii), Sections 2(g)(A), (B) and (C) shall apply only to those compounds, Collaboration Lead Compounds, Independent Lead Compounds and Products for which Development or co-promotion shall have been terminated and/or to those compounds or Lead Compounds that have not been designated previously a Collaboration Lead Compound in accordance with Section 3(b) or an Independent Lead Compound in accordance with Section 3(m); provided further that in the event that JT elects to pursue a Discontinued Compound or a Non-Proposed Compound on or before the first anniversary of the expiration or termination of the Research Program Term pursuant to Section 3(b)(iii) or 3(b)(iv), respectively, Sections 2(g)(A), (B) and (C) shall not apply to such Discontinued Compound or Non-Proposed Compound until such time as JT shall have terminated the Development or co-promotion of such Discontinued Compound or Non- Proposed Compound. Tularik will then be free to pursue clinical development and registration of such compounds, Lead Compounds and/or Products without obligation to JT except as provided in Section 4(f) or Section 5(c), as appropriate.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Research Plan The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6.

Time is Money Join Law Insider Premium to draft better contracts faster.